• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Sol-Gel Technologies Ltd.

    1/31/24 6:00:48 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLGL alert in real time by email
    SC 13G 1 zk2430847.htm SC 13G zk1617981.htm

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
    (Amendment No. __)
    (Rule 13d-102)
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d)
    AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)
     
    Under the Securities Exchange Act of 1934
     
    Sol-Gel Technologies Ltd.
    (Name of Issuer)
     
    Ordinary Shares
    (Title of Class of Securities)
     
     
    M8694L103
     
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
    Check the following box to designate the rule pursuant to which the Schedule is filed:
     
    ☐ Rule 13d-1(b)
     
    ☒ Rule 13d-1(c)
     
    ☐ Rule 13d-1(d)
     
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     
    CUSIP NO.  M8694L103
     
    1.
    Name of Reporting Person
     
    Migdal Insurance & Financial Holdings Ltd
    2.
    Check the Appropriate Box if a Member of a Group
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     
     
    4.
    Place of Organization
     
    Israel
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5.
    Sole Voting Power
     
     
    6.
    Shared Voting Power
     
    1,227,548 Ordinary Shares *
    7.
    Sole Dispositive Power
     
     
    8.
    Shared Dispositive Power
     
    1,227,548 Ordinary Shares *
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,227,548 Ordinary Shares *
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
     
    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    5.31%**
    12.
    Type of Reporting Person :               
     
    HC

    *See Item 4.
    ** Based on 23,119,068 ordinary shares issued and outstanding as of December 31, 2023 (according to publicly available information provided by the issuer).

    Page 2 of 5 pages


    Item 1.
     
    (a)
    Name of Issuer:
     
    Sol-Gel Technologies Ltd.
     
    (b)
    Address of Issuer’s Principal Executive Offices:
     
    Golda Meir 7, Ness Ziona 7403650
     
    Item 2.
     
    (a)-(c)     Name of Person Filing, address and citizenship:

    The foregoing entity is referred to as the “Reporting Person” in this Statement:
     
    Migdal Insurance & Financial Holdings Ltd., an Israeli public company, with a principal business address at  4 Efal Street; P.O. Box 3063; Petach Tikva 49512, Israel.
     
    (d)
    Title of Class of Securities:
     

    Ordinary Shares, NIS 0.01 par value per share (the “Ordinary Shares”)
     
    (e)
    CUSIP Number:
     

    M8694L103
     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     

    Not Applicable.
     
    Item 4.
    Ownership
     
    Of the 1,227,548 Ordinary Shares reported in this Statement as beneficially owned by the Reporting Person (i) 1,227,548 Ordinary Shares are held for members of the public through, among others, provident funds, mutual funds, pension funds and insurance policies, which are managed by direct and indirect subsidiaries of Reporting Person, each of which subsidiaries operates under independent management and makes independent voting and investment decisions, and (ii)  - Ordinary Shares are held by companies for the management of funds for joint investments in trusteeship, each of which operates under independent management and makes independent voting and investment decisions, and (iii) - are beneficially held for their own account (Nostro account). Consequently, this Statement shall not be construed as an admission by the Reporting Person that it is the beneficial owner of 1,227,548 Ordinary Shares reported in this Statement except as set forth above, see items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which are incorporated herein.
     
    Item 5.
    Ownership of Five Percent or Less of a Class
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
     

    Not Applicable.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
     

    See Exhibit below.
     
    Item 8.
    Identification and Classification of Members of the Group
     

    Not Applicable.
     
    Item 9. 
    Notice of Dissolution of Group
     

    Not Applicable.
     
    Page 3 of 5 pages

     
    Item 10.
    Certification
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
    Exhibit to Item 7
     
    The subsidiaries of reporting person may make independent voting and/or investment decisions for client accounts include:
     
    Subsidiary Name
    Type of Subsidiary
    Migdal Insurance Company ltd.
    FI
    Migdal Makefet Pension and Provident Funds ltd.
    FI
    Migdal Mutual Funds Ltd
    FI

    [SIGNATURE PAGE TO FOLLOW]
     
    Page 4 of 5 pages

     
    SIGNATURES
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    January 30, 2024
     
     
    MIGDAL INSURANCE AND FINANCIAL HOLDINGS LTD.
     
    BY: /s/ Yosef Ben Baruch & Tal Cohen
    authorized signatories of MIGDAL INSURANCE AND FINANCIAL HOLDINGS LTD.

    Page 5 of 5 pages

            
    Get the next $SLGL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLGL

    DatePrice TargetRatingAnalyst
    8/19/2024$6.00 → $4.00Strong Buy → Outperform
    Raymond James
    10/21/2022$5.50Hold
    Jefferies
    11/15/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    11/12/2021$23.00 → $21.00Strong Buy
    Raymond James
    7/28/2021$20.00 → $21.00Buy
    HC Wainwright & Co.
    7/12/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SLGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sol-Gel Announces Health Canada Approval of EPSOLAY®

    NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, a Phase-1b, double blinded clinical trial of SGT-210 (erlotinib ointment, 5%) on Darier disease patients and with two approved large-category dermatology products, TWYNEO and EPSOLAY, announced today that on August 27, 2025 Health Canada issued a Notice of Compliance (NOC) for EPSOLAY for the treatment of inflammatory lesions of rosacea in adults. This approval comes as a result of Sol-Gel's partnership with Searchlig

    9/4/25 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

    Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026Phase-1b proof-of-concept clinical trial of SGT-210 for Darier disease is ongoingSol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S. for a total consideration of $16 million to be received during 2025Following recent transactions, Sol-Gel's cash runway is expected to extend into the first quarter of 2027 NESS ZIONA, Israel, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting

    8/15/25 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Reports First Quarter 2025 Results

    NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter Year Ended March 31st, 2025 Total revenue in the first quarter was $1 million compared to $0.5 million revenues for the same period in 2024. Research and development expenses were $8.8 million compared to $5.3 million in the same period in 2024. The increase of $3.5 million was primarily attributed to an increase of $3.6 million due to expenses associated with supplier-led ma

    5/23/25 7:15:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sol-Gel downgraded by Raymond James with a new price target

    Raymond James downgraded Sol-Gel from Strong Buy to Outperform and set a new price target of $4.00 from $6.00 previously

    8/19/24 6:57:49 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Sol-Gel with a new price target

    Jefferies resumed coverage of Sol-Gel with a rating of Hold and set a new price target of $5.50

    10/21/22 7:42:15 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Sol-Gel Technologies with a new price target

    HC Wainwright & Co. reiterated coverage of Sol-Gel Technologies with a rating of Buy and set a new price target of $20.00 from $21.00 previously

    11/15/21 1:18:47 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TWYNEO issued to SOL-GEL TECHNOLOGIES LTD

    Submission status for SOL-GEL TECHNOLOGIES LTD's drug TWYNEO (ORIG-1) with active ingredient TRETINOIN;BENZOYL PEROXIDE has changed to 'Approval' on 07/26/2021. Application Category: NDA, Application Number: 214902, Application Classification: Type 4 - New Combination

    7/27/21 10:39:03 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    SEC Filings

    View All

    SEC Form 6-K filed by Sol-Gel Technologies Ltd.

    6-K - Sol-Gel Technologies Ltd. (0001684693) (Filer)

    9/4/25 7:00:10 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Sol-Gel Technologies Ltd.

    SCHEDULE 13G - Sol-Gel Technologies Ltd. (0001684693) (Subject)

    8/29/25 4:05:24 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Sol-Gel Technologies Ltd.

    EFFECT - Sol-Gel Technologies Ltd. (0001684693) (Filer)

    8/19/25 12:15:02 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Financials

    Live finance-specific insights

    View All

    Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

    An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib gel, 2%), an Orphan Drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome and partnered with Galderma to commercialize two approved lar

    3/13/24 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

    Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Phase 1 trial for SGT-210 (erlotinib) demonstrated no systemic absorption-related adverse events; Sol-Gel intends to advance this drug candidate Sol-Gel has cash runway into the second half of 2025 NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched in the U.S., SGT-610, which is Phase 3

    5/12/23 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

    Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndromeA Phase 3 study of SGT-610 is expected to initiate in the second half of 2023, with results expected by the end of 2025The base of recurrent TWYNEO® prescribers was 82% in Q4 2022, while the EPSOLAY® recurrent prescriber base has grown to 64% during the same periodFollowing recent financing, Sol-Gel's cash runway expected to extend into the second half of 2025 NESS ZIONA, Israel, March 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company wi

    3/10/23 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd.

    SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

    11/14/24 4:37:49 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd.

    SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

    11/14/24 6:17:23 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Sol-Gel Technologies Ltd. (Amendment)

    SC 13D/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

    4/8/24 9:28:09 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Leadership Updates

    Live Leadership Updates

    View All

    Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

    Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September

    11/15/24 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribersSol-Gel's cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the third quarter ended September 30, 2022 and provided a corporate update. Alon Seri-Levy, PhD, Chief Executive Officer of Sol-Gel, stated, "We are very pleased with the continu

    11/10/22 4:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

    NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today the appointment of Michael Glezin to the position of Vice President, Business Development. In this position, Mr. Glezin will be responsible for identifying new in-licensing business opportunities as well as potential commercial partners for the Company's approved products in ex-US territories. "We are very pleased to have Michael join the Company as we expand our business development efforts," stated Alon Seri-Levy,

    10/3/22 8:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care